Celldex Therapeutics, Inc. (CLDX)

$27.52

-0.47

(-1.68%)▲

Market is closed - opens 7 PM, 02 Oct 2023

Insights on Celldex Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 1.61M → 268.0K (in $), with an average decrease of 56.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -26.48M → -30.50M (in $), with an average decrease of 7.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 82.6% return, outperforming this stock by 84.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 162.0% return, outperforming this stock by 76.4%

Performance

  • $27.08
    $28.33
    $27.52
    downward going graph

    1.62%

    Downside

    Day's Volatility :4.43%

    Upside

    2.86%

    downward going graph
  • $24.89
    $48.40
    $27.52
    downward going graph

    9.56%

    Downside

    52 Weeks Volatility :48.57%

    Upside

    43.14%

    downward going graph

Returns

PeriodCelldex Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-18.89%
-3.0%
0.0%
6 Months
-22.65%
0.5%
0.0%
1 Year
-2.1%
6.3%
6.3%
3 Years
85.57%
22.1%
17.3%

Highlights

Market Capitalization
1.3B
Book Value
$5.87
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.49
PEG Ratio
0.0
Wall Street Target Price
59.57
Profit Margin
0.0%
Operating Margin TTM
-3726.4%
Return On Assets TTM
-21.58%
Return On Equity TTM
-35.21%
Revenue TTM
3.3M
Revenue Per Share TTM
0.07
Quarterly Revenue Growth YOY
64.4%
Gross Profit TTM
-79.9M
EBITDA
-118.4M
Diluted Eps TTM
-2.49
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.63
EPS Estimate Next Year
-2.98
EPS Estimate Current Quarter
-0.67
EPS Estimate Next Quarter
-0.68

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Celldex Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 116.46%

Current $27.52
Target $59.57

Company Financials

FY17Y/Y Change
Revenue
12.7M
↑ 87.78%
Net Income
-93.0M
↓ 27.62%
Net Profit Margin
-730.06%
↑ 1163.99%
FY18Y/Y Change
Revenue
9.5M
↓ 25.15%
Net Income
-151.2M
↑ 62.51%
Net Profit Margin
-1.6K%
↓ 855.01%
FY19Y/Y Change
Revenue
3.6M
↓ 62.54%
Net Income
-50.9M
↓ 66.35%
Net Profit Margin
-1.4K%
↑ 161.11%
FY20Y/Y Change
Revenue
7.4M
↑ 107.61%
Net Income
-59.8M
↑ 17.5%
Net Profit Margin
-805.88%
↑ 618.08%
FY21Y/Y Change
Revenue
4.7M
↓ 37.3%
Net Income
-70.5M
↑ 17.95%
Net Profit Margin
-1.5K%
↓ 710.16%
FY22Y/Y Change
Revenue
2.4M
↓ 49.32%
Net Income
-112.3M
↑ 59.3%
Net Profit Margin
-4.8K%
↓ 3249.55%
Q1 FY22Q/Q Change
Revenue
174.0K
↓ 47.9%
Net Income
-23.1M
↑ 14.4%
Net Profit Margin
-13.2K%
↓ 7214.79%
Q2 FY22Q/Q Change
Revenue
163.0K
↓ 6.32%
Net Income
-36.0M
↑ 56.2%
Net Profit Margin
-22.1K%
↓ 8841.21%
Q3 FY22Q/Q Change
Revenue
407.0K
↑ 149.69%
Net Income
-26.8M
↓ 25.61%
Net Profit Margin
-6.6K%
↑ 15507.5%
Q4 FY22Q/Q Change
Revenue
1.6M
↑ 296.31%
Net Income
-26.5M
↓ 1.11%
Net Profit Margin
-1.6K%
↑ 4938.74%
Q1 FY23Q/Q Change
Revenue
967.0K
↓ 40.05%
Net Income
-29.4M
↑ 10.85%
Net Profit Margin
-3.0K%
↓ 1394.2%
Q2 FY23Q/Q Change
Revenue
268.0K
↓ 72.29%
Net Income
-30.5M
↑ 3.89%
Net Profit Margin
-11.4K%
↓ 8345.04%
FY17Y/Y Change
Total Assets
315.6M
↓ 17.67%
Total Liabilities
79.3M
↓ 32.79%
FY18Y/Y Change
Total Assets
155.8M
↓ 50.63%
Total Liabilities
31.7M
↓ 59.94%
FY19Y/Y Change
Total Assets
122.9M
↓ 21.1%
Total Liabilities
28.9M
↓ 8.95%
FY20Y/Y Change
Total Assets
235.8M
↑ 91.84%
Total Liabilities
26.5M
↓ 8.39%
FY21Y/Y Change
Total Assets
444.7M
↑ 88.54%
Total Liabilities
25.2M
↓ 4.92%
FY22Y/Y Change
Total Assets
352.7M
↓ 20.67%
Total Liabilities
26.5M
↑ 5.37%
Q1 FY22Q/Q Change
Total Assets
424.0M
↓ 4.64%
Total Liabilities
25.9M
↑ 3.03%
Q2 FY22Q/Q Change
Total Assets
403.0M
↓ 4.97%
Total Liabilities
37.9M
↑ 45.98%
Q3 FY22Q/Q Change
Total Assets
369.2M
↓ 8.37%
Total Liabilities
23.8M
↓ 37.12%
Q4 FY22Q/Q Change
Total Assets
352.7M
↓ 4.47%
Total Liabilities
26.5M
↑ 11.43%
Q1 FY23Q/Q Change
Total Assets
324.5M
↓ 8.0%
Total Liabilities
21.8M
↓ 17.91%
Q2 FY23Q/Q Change
Total Assets
299.3M
↓ 7.77%
Total Liabilities
21.8M
↓ 0.02%
FY17Y/Y Change
Operating Cash Flow
-99.9M
↓ 11.59%
Investing Cash Flow
46.5M
↓ 32.56%
Financing Cash Flow
51.3M
↑ 254.16%
FY18Y/Y Change
Operating Cash Flow
-75.2M
↓ 24.71%
Investing Cash Flow
29.8M
↓ 35.84%
Financing Cash Flow
29.4M
↓ 42.6%
FY19Y/Y Change
Operating Cash Flow
-46.4M
↓ 38.31%
Investing Cash Flow
17.1M
↓ 42.72%
Financing Cash Flow
16.3M
↓ 44.78%
FY20Y/Y Change
Operating Cash Flow
-40.4M
↓ 12.95%
Investing Cash Flow
-98.2M
↓ 675.05%
Financing Cash Flow
171.2M
↑ 953.24%
FY21Y/Y Change
Operating Cash Flow
-60.9M
↑ 50.75%
Investing Cash Flow
-216.2M
↑ 120.08%
Financing Cash Flow
272.4M
↑ 59.07%
Q1 FY22Q/Q Change
Operating Cash Flow
-24.5M
↑ 68.93%
Investing Cash Flow
10.4M
↓ 154.79%
Financing Cash Flow
304.0K
↓ 28.64%
Q2 FY22Q/Q Change
Operating Cash Flow
-22.2M
↓ 9.33%
Investing Cash Flow
25.3M
↑ 143.55%
Financing Cash Flow
71.0K
↓ 76.64%
Q3 FY22Q/Q Change
Operating Cash Flow
-35.2M
↑ 58.21%
Investing Cash Flow
23.1M
↓ 8.75%
Financing Cash Flow
2.3M
↑ 3147.89%
Q1 FY23Q/Q Change
Operating Cash Flow
-28.6M
↑ 31.28%
Investing Cash Flow
52.6M
-
Financing Cash Flow
694.0K
↓ 50.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-27.2M
↓ 4.81%
Investing Cash Flow
1.2M
↓ 97.79%
Financing Cash Flow
133.0K
↓ 80.84%

Technicals Summary

Sell

Neutral

Buy

Celldex Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
-0.79%
-22.65%
-2.1%
85.57%
316.97%
Moderna, Inc.
Moderna, Inc.
-11.43%
-29.94%
-12.65%
45.99%
455.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-1.44%
1.41%
19.47%
47.01%
108.75%
Novo Nordisk A/s
Novo Nordisk A/s
-3.29%
15.05%
82.56%
161.96%
290.64%
Seagen, Inc.
Seagen, Inc.
2.56%
4.47%
55.05%
8.41%
161.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.86%
11.4%
20.1%
27.79%
81.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
NA
NA
0.0
-2.63
-0.35
-0.22
0.0
5.87
Moderna, Inc.
Moderna, Inc.
34.94
34.94
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.08
22.08
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.05
43.05
2.03
1.64
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.67
26.67
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
Buy
$1.3B
316.97%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.2B
455.32%
34.94
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.6B
108.75%
22.08
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$412.6B
290.64%
43.05
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$39.8B
161.4%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$89.7B
81.52%
26.67
35.4%

Institutional Holdings

  • FMR Inc

    15.00%

  • Wellington Management Company LLP

    10.86%

  • RTW INVESTMENTS, LLC

    7.33%

  • BlackRock Inc

    6.82%

  • State Street Corporation

    5.77%

  • Kynam Capital Management, LP

    5.50%

Corporate Announcements

  • Celldex Therapeutics, Inc. Earnings

    Celldex Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Organization
Celldex Therapeutics, Inc.
Employees
148
CEO
Mr. Anthony S. Marucci M.B.A.
Industry
Health Technology

Discover More

FAQs